Ke Pros
Why now: Unlike an earlier study the current neuropsychiatric project comprises more elaborate assessments, and for the first time involves MRI and electrophysiological investigations. Identical assessment methods with AMP SCZ promise a broad array of data that can be validly compared with that from other global populations.
Intended outcome: A major benefit of KePROS is its biomarker research capacity building in Kenya, which will facilitate future investigations beyond the current study.
Funding support: National Institutes of Health (NIH).
Lead Researchers: Professor David Ndetei, Daniel Mamah, MD, Dr Victoria Mutiso.
